Viewing Study NCT05471856


Ignite Creation Date: 2025-12-24 @ 11:32 PM
Ignite Modification Date: 2026-01-02 @ 1:51 PM
Study NCT ID: NCT05471856
Status: RECRUITING
Last Update Posted: 2025-12-17
First Post: 2022-07-21
Is NOT Gene Therapy: True
Has Adverse Events: False

Brief Title: A Study to Test How Different Doses of BI 1703880 in Combination With Ezabenlimab Are Tolerated in People With Different Types of Advanced Cancer (Solid Tumours)
Sponsor: Boehringer Ingelheim
Organization:

Study Modules

Identification Module Status Module Sponsor Collaborators Module Oversight Module Description Module Conditions Module Design Module Arms Interventions Module Outcomes Module Eligibility Module Contacts Locations Module References Module